

■ Time Table
Day 3, July 20 (Sat)

7月2日現在

		7	8	9	10	11	12	13	14	15	16	17	18	19	
Kyoto International Conference Center	Main Hall	1F	O3-1 Gastrointestinal Cancer2	PS3 Presidential Session 3	MeS-30 Cancer Immunotherapy Guidelines and Adverse Event Management	PSY8 Advances and Future Perspectives of Cell Therapy	Best of JSMO	Closing Remarks							
	Annex 1	1F	PD3 Implementation of Genome Medicine in Lung Cancer	EL30 Treatment of Multiple Myeloma: Current Status and a Future Perspective	EL31 The Latest Pharmacotherapies in Gastroenteropancreatic Neuroendocrine Tumors	EL32 Upfront in Drug Therapy of Advanced Melanoma	MeS-31 Perspective on the current & future treatment of Gastric Cancer	EL33 Cancer of Unknown Primary	EL34 Pediatric, Adolescent and Young Adult Cancer	EL35 Hereditary Cancer, to Find and to be Found	SY14 Treatment Strategy for Advanced Testicular Germ Cell Tumors (Refractory Cases)				
	Annex2	1F	MoS-8 Update on gastric cancer medication	SY15 Cutting Edge of CML Treatment	PPD1 Patients Involvement in Clinical Trials	MeS-32 Treatment Strategy for Lenalidomide-Refractory Multiple Myeloma	MO3-1 Hematologic Malignancies 1	PSY9 Efforts by Industry-government-academia for Clinical Use of New Technology - Interstellar Communication -							
	Room A	2F	MoS-9 Change with the Changing Times: Mono to Combo: Restoration of Lung Cancer Treatment	PSY10 Basic Knowledge of Genetic Testing that Can Lead to the Diagnosis of Hereditary Tumors	SY16 Management of Delirium in Cancer Patients	EL36 Current Treatment Strategies for Brain Tumors and Metastases	MeS-33 Nivolumab use in Gastric Cancer: Long-term follow-up data from the Attraction-2 Trial	MO3-2 Gastrointestinal Cancer8 (GIST/Small Bowel Cancer/ Colorectal Cancer)	PSY11 Psycho-oncology: Has Communication between Patients and Medical Professionals Changed as Cancer Treatment Progressed?		PSY12 Self-management for Cancer Survivors				
	Room B-1	2F	MoS-10 Development and usefulness of scalp cooling device for hair loss reduction in breast cancer chemotherapy	MO3-3 Head and Neck Cancer3	PS3 Presidential Session 3 (relay)	MeS-34 Second-Line Strategies in the Treatment of Metastatic Colorectal Cancer		PPD2 Nurses' Role in Treating and Preserving Reproductive Function of Cancer Patients	PSY13 Role of Social Workers in Oncology - Consider How Social Workers Should Demonstrate Their Expertise in Cancer Care -						
	Room D	1F		SY17 Future Direction of Immunotherapy for Head and Neck Cancer	PSY14 "Appearance Care" - Consider Medical, Cosmetic, and Psychosocial Support based on the Latest Information -	MeS-35 Clinical Trials - Ideal Design in the New Era		PD4 Chemotherapy for Rare Gynecological Malignancies	PSY15 What Should We Do to Activate Clinical Research of Supportive Care by Medical Staff						
	Room E	1F		MO3-4 Translational Research5	MO3-5 Translational Research6	MO3-6 Translational Research7 (cf/ctDNA)	MO3-7 Lung Cancer/Thoracic Cancer8 (NSCLC - Immune Checkpoint Inhibitors3)	MeS-36 The treatment of advanced squamous cell carcinoma	MO3-8 Breast Cancer4	MO3-9 Lung Cancer/Thoracic Cancer9 (NSCLC - Immune Checkpoint Inhibitors4)		PSY16 Role of Rehabilitation and Nutrition to Improve the Outcome of Chemotherapy Treated Patients			
	Sakura	1F	MoS-11 Emerging systemic therapies for hepatocellular carcinoma	DL13 Current scenario for Immunotherapy in Lung Cancer	EL37 Clinical Application of Multiple Gene Testing for Precision Oncology	SY18 Unmet Needs of Cancer Chemotherapy in Patients with Malignancy	MeS-37 The importance of optimal drug sequencing in mCRC	JSJS JCOG/SIOG/JSMO Joint Symposium Cancer Chemotherapy in the Elderly Patients: Current and Future Prospects	SY19 Cancer Associated Cognitive Decline (CACC): State of the Art of Mechanism, Diagnosis, and Treatment						
Swan	1F		MO3-10 Cross-sectional Program2 (Immune Checkpoint Inhibitors)	MO3-11 Cross-sectional Program3 (Others)	MO3-12 Gastrointestinal Cancer9 (Colorectal Cancer2)	MO3-13 Hematologic Malignancies2	MeS-38 Update on the therapeutic strategies in ovarian cancer	Medical Oncology Seminar Part 1 Case Conference	Medical Oncology Seminar Part 2 Symposium	Medical 16:50-17:30 Oncology Seminar Part 3					
Grand Prince Hotel Kyoto	Royal Room	1F		PD5 Medical Cooperation and Comprehensive Social Management for Rare Cancers	SY20 Progress of Drug Therapy for Soft Tissue Sarcoma	MeS-39 The present and future of Blinatumomab in B-precursor acute lymphoblastic leukemia	MeS-40 Clinical implementation of NCC Oncopanel System	PPD3 Issues and Perspectives for Collaboration in Head and Neck Cancer Care	PSY17 Current State and Future of Direct to Consumer Service						
	Rose Room	B1F		JSMO Committee on Guideline Program 1 Overview of Cancer Drug Therapy Guidelines for Elderly Patients	JSMO Committee on Guideline Program 2 Guidance of Gene-testing in Colorectal Cancer	O3-2 Gynecologic Cancer	MeS-41 Cancer Associated Thrombosis	JS5 Joint Symposium 5 (JSPM/JSMO) Advanced Care Planning in Cancer Care	JS6 Joint Symposium 6 (JSCN/JSMO) Multidisciplinary Care Required for Precision Medicine						
	Gold Room	B2F	MoS-12 Tumor Agnostic Treatments Strategy : A Changing Paradigm	PD6 The Best Care and Treatment for Breast Cancer Patients with BRCA Mutation	MS4 Treatment Strategy for Patient with Urological Cancer Having Complications										
Kyoto International Conference Center	Room C-1	1F					MeS-44 The latest Treatment Strategy with Ibrance for R-Positive/HER2-negative Metastatic Breast Cancer - Through Experience for one and a half year-			UD Urgent Debate: Latest Evidence and Future Perspective of 1st Line Therapy for Advanced Gastric Cancer					
	Room C-2	1F					MeS-42 Long term survival in I-O Era	DL14 Expression of Angiotensin-like 4 Fibronectin-Like Domain increases risk of brain metastases in women with breast cancer.	DL18 Peri-operative adjuvant treatment for potential resectable NSCLC						
	Room B-2	2F	DL15 Hematopoietic Stem Cell Expansion	DL16 Chemoradiotherapy in Adjuvant Therapy of Curatively Resected Pancreatic Cancer: Lesions from TCOG T3207 Study	DL17 Immuno-precision medicine in gastric cancer: How to select the proper patients?										
	Room 104 (Meet the Experts)	1F	ME13 Interpretation the Results of Adjuvant Chemotherapy in Curatively Resected Pancreatic Cancer	ME14 Systemic Approach to Clinical Trial Result Interpretation	ME15 Breast Cancer in the East Versus the West: Followed by Interactive Session on Establishing Collaborations			ME16 Latest Advances in Hematopoietic Stem Cell Transplantation	ME17 Novel Therapies for AML						
	Room 510 (Patient Advocate Program)	5F		PAP 支持療法と緩和ケア	PAP がんリハビリテーション	PAP ランチンセミナー: がん心のケア		PAP がんと口腔ケア	PAP がんとピアランスケア (外見のケア)	PAP がんと栄養					
	Event Hall-New Hall (Poster Area)	1F		Putting up posters	Poster Display	Poster Session									
		7	8	9	10	11	12	13	14	15	16	17	18	19	

Explanatory Notes

- PS = Presidential Session
- JSJS = JCOG/SIOG/JSMO Joint Symposium
- JS = Joint Symposium
- PSY = Presidential Symposium
- PPD = Presidential Panel Discussion
- PWS = Presidential Workshop
- UD = Urgent Debate
- SY = Symposium
- MS = Mini Symposium
- PD = Panel Discussion
- EL = Educational Lecture
- DL = Distinguished Expert Lecture
- ME = Meet the Experts
- MoS = Morning Seminar
- O = Oral Abstract Session
- MO = Mini-Oral Abstract Session
- P = Poster
- Ⓜ = Simultaneous Interpretation (E&J)
- E = English Session